|
Drug development or preclinical development is defined in many pharmaceutical companies as the process of taking a new chemical lead through the stages necessary to allow it to be tested in human clinical trials, although a broader definition would encompass the entire process of drug discovery and clinical testing of novel drug candidates. In health care, including medicine, a clinical trial (synonyms: clinical studies, research protocols, medical research) is a process in which a medicine or other medical treatment is tested for its safety and effectiveness, often in comparison to existing treatments. ...
New chemical entity (NCE) development
New chemical entities (NCEs) are compounds which emerge from the process of drug discovery. These will have promising activity against a particular biological target thought to be important in disease, however little will be known about the safety, toxicity, pharmacokinetics and metabolism of this NCE in humans. It is the function of drug development to assess all of these parameters prior to human clinical trials. A further major objective of drug development is to make a recommendation of the dose and schedule to be used the first time an NCE is used in a human clinical trial ("first-in-man", FIM). According to the U.S. Food and Drug Administration, a new chemical entity means a drug that contains no active moiety that has been approved by FDA in any other application submitted under section 505(b) of the Food, Drug and Cosmetic Act. ...
In medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are discovered and/or designed. ...
// Toxic and Intoxicated redirect here – toxic has other uses, which can be found at Toxicity (disambiguation); for the state of being intoxicated by alcohol see Drunkenness. ...
Pharmacokinetics (in Greek: pharmacon meaning drug, and kinetikos meaning putting in motion) is a branch of pharmacology dedicated to the determination of the fate of substances administered externally to a living organism. ...
Structure of the coenzyme adenosine triphosphate, a central intermediate in energy metabolism. ...
A first-in-man study is a clinical trial where a medical procedure, previously developed and assessed through in vitro or animal testing, or through mathematical modelling is tested on human subjects for the first time. ...
In addition, drug development is required to establish the physicochemical properties of the NCE: its chemical makeup, stability, solubility. The process by which the chemical is made will be optimized so that from being made at the bench on a milligram scale by a synthetic chemist, it can be manufactured on the kilogram and then on the ton scale. It will be further examined for its suitability to be made into capsules, tablets, aeresol, intramuscular injectable, subcuteneous injectable, or intravenous formulations. Together these processes are known in preclinical development as CMC: Chemistry, Manufacturing and Control. The milligram (symbol mg) is an SI unit of mass. ...
Kg redirects here. ...
Look up ton in Wiktionary, the free dictionary. ...
Look up capsule in Wiktionary, the free dictionary. ...
For other meanings please see Tablet (disambiguation) Common disk-shaped pills A pharmacological tablet is a medicinal or other active substance mixed with binder powders and pressed into a tablet form. ...
An intravenous drip in a hospital Intravenous therapy or IV therapy is the administration of liquid substances directly into a vein. ...
Many aspects of drug development are focused on satisfying the regulatory requirements of drug licensing authorities. These generally constitute a number of tests designed to determine the major toxicities of a novel compound prior to first use in man. It is a legal requirement that an assessment of major organ toxicity be performed (effects on the heart and lungs, brain, kidney, liver and digestive system), as well as effects on other parts of the body that might be affected by the drug (e.g. the skin if the new drug is to be delivered through the skin). While, increasingly, these tests can be made using in vitro methods (e.g. with isolated cells), many tests can only be made by using experimental animals, since it is only in an intact organism that the complex interplay of metabolism and drug exposure on toxicity can be examined. To meet Wikipedias quality standards, this article or section may require cleanup. ...
In vitro (Latin: within the glass) refers to the technique of performing a given experiment in a test tube, or, generally, in a controlled environment outside a living organism. ...
The process of drug development does not stop once an NCE begins human clinical trials. In addition to the tests required to move a novel drug into the clinic for the first time it is also important to ensure that long-term or chronic toxicities are determined, as well as effects on systems not previously monitored (fertility, reproduction, immune system, etc). The compound will also be tested for its ability to cause cancer (carcinogenicity testing).
If a compound emerges from these tests with an acceptable toxicity and safety profile, and it can further be demonstrated to have the desired effect in clinical trials, then it can be submitted for marketing approval in the various countries where it will be sold. In the US, this process is called a New Drug Application or NDA. Most NCEs, however, will fail during drug development, either because they have some unacceptable toxicity, or because they simply do not work in clinical trials. The New Drug Application (NDA) is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S. The goals of the NDA are to provide enough information to permit FDA reviewer to reach the following: Is the drug...
As this drug discovery process becomes more expensive it is becoming important to look at new ways to bring forward NCEs. One approach to improve efficiency is to recognize that there are many steps requiring different levels of experimentation. The early phase of drug discovery actually has components of real innovation, components of experimentation and components that involve set routines. This model of Innovation, Experimentation, and Commoditization ensures that new ways to do work are adopted continually. This model also allows the discipline to use appropriate internal and external resources for the right work.
Cost Studies published in 2003 report an average pre-tax cost of approximately $800 million to bring a new drug (i.e. a drug with a New Chemical Entity) to market.[1][2]
A study published in 2006 estimates that costs vary from around 500 million to 2,000 million dollars depending on the therapy or the developing firm.[3]
These figures relate only to new, innovative drugs (drugs with a New Chemical Entity NCE, also called New Active Substance NAS). Each year, worldwide, only about 26 such drugs enter the market (2005: 26, 2004: 24, 2003: 26, 2002: 28). The development cost of the thousands of other drugs are much smaller. The $800 million quoted include the cost of all drug development which did not result in a new drug. It also includes some 400 million $ of opportunity costs. Opportunity cost is a term used in economics, to mean the cost of something in terms of an opportunity foregone (and the benefits that could be received from that opportunity), or the most valuable foregone alternative. ...
The consumer advocacy group Public Citizen suggests on its web site that the actual cost is under $200 million, about 29% of which is spent on FDA-required clinical trials.[4] Public Citizen is a U.S. non-governmental organization, founded by Ralph Nader in 1971 and based in Washington, DC. Its activities span across a diverse range of issues, including energy policy, trade policy, campaign finance reform and accountability, consumer protection, medical malpractice, and public health. ...
In health care, including medicine, a clinical trial (synonyms: clinical studies, research protocols, medical research) is a process in which a medicine or other medical treatment is tested for its safety and effectiveness, often in comparison to existing treatments. ...
See also The Belmont Report is a report created by the former dee dee dee (which was renamed to Health and Human Services) entitled Ethical Principles and Guidelines for the Protection of Human Subjects of Research and is an important historical document in the field of medical ethics. ...
In health care, including medicine, a clinical trial (synonyms: clinical studies, research protocols, medical research) is a process in which a medicine or other medical treatment is tested for its safety and effectiveness, often in comparison to existing treatments. ...
A Clinical Trial Protocol is a document that describes the objective(s), design, methodology, statistical considerations, and organization of a clinical trial. ...
Clinical Data Interchange Standards Consortium (CDISC) is a non-profit organization, whose mission is to develop and support global, platform-independent data standards that enable information system interoperability to improve medical research and related areas of healthcare. Their main project, the described data standard, bears the same name. ...
Chemogenomics can be defined as a genomic response to chemical compounds. ...
Drug discovery depends on methods by which many different chemicals are assayed for their activity. ...
The Council for International Organizations of Medical Sciences (CIOMS) is an international, nongovernmental, not-for-profit organization established jointly by WHO and UNESCO in 1949. ...
Drug design is the approach of finding drugs by design, based on their biological targets. ...
In medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are discovered and/or designed. ...
Early drug discovery involves several phases from Target identification to preclinical development. ...
The European Medicines Agency (EMEA) is a European agency for the evaluation of medicinal products. ...
“FDA†redirects here. ...
A generic drug (pl. ...
Good clinical practice is a set of rules and regulations that is provided by International Conference on Harmonisation (ICH) - an international body that regulates clinical trials involving human subjects. ...
The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is a project that brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects of pharmaceutical...
Medical ethics is primarily a field of applied ethics, the study of moral values and judgments as they apply to medicine. ...
Nonclinical / Pre-Clinical Studies of Drug / Product Candidates Pre-Clinical Studies should be done on animals, before the permit of clinical trial on humans could be obtained. ...
A pharmaceutical company, or drug company, is a commercial business whose focus is to research, develop, market and/or distribute drugs, most commonly in the context of healthcare. ...
Pharmaceutical marketing is the business of advertising or otherwise promoting the sale of pharmaceuticals or drugs. ...
Pharmaceutical Research and Manufacturers of America (PhRMA) is a trade group representing the pharmaceutical research and biotechnology companies in the United States. ...
Activities that need to be performed and results to be obtained a before a clinical trial in humans can begin. ...
To meet Wikipedias quality standards, this article or section may require cleanup. ...
The World Health Organization (WHO) Model List of Essential Medicines is a guideline for national governments that want to ensure they have an inventory of medicines needed by every health system. ...
The World Medical Association (WMA), an international organization of physicians, was formally established on 17 September 1947, pursuant to deliberations and decisions taken in the First General Assembly of WMA held in Paris, France. ...
References - ^ DiMasi J. "The value of improving the productivity of the drug development process: faster times and better decisions". Pharmacoeconomics 20 Suppl 3: 1-10. PMID 12457421.
- ^ DiMasi J, Hansen R, Grabowski H (2003). "The price of innovation: new estimates of drug development costs". J Health Econ 22 (2): 151-85. PMID 12606142. .
- ^ Adams C, Brantner V. "Estimating the cost of new drug development: is it really 802 million dollars?". Health Aff (Millwood) 25 (2): 420-8. PMID 16522582.
- ^ http://www.citizen.org/congress/reform/drug_industry/articles.cfm?ID=6532
External links - Drug Development Technology Projects, companies and industry news
- CDER Drug and Biologic Approval Reports
- International Union of Basic and Clinical Pharmacology
- Information of Drugs Research & Development
|
Feeds |
Contact